Pharmacology of Haemostatis and Thrombosis Flashcards

1
Q

Platelet Activation and Adhesion

A
  • endothelial injury exposes sub-endothelial
    collagen
  • Von Willebrand factor binds to the exposed
    collagen
  • other side of Von Willebrand Factor has
    binding sites for platelets via GP IB-IX-V
    complex (glycoprotein)
  • tethers platelets to Von Willebrand factor
    which is tethered to exposed sub-
    endothelial collagen
  • platelets stick to other platelets and big
    platelet plug is formed
  • platelets become activated upon binding to
    Von Willebrand’s Factor
  • activated platelets can now bind to
    fibrinogen
  • via specific binding glycoproteins: GPIIbIIIa
    (GP2b3a)
  • facilitates further platelet aggregation
    (clustering)
  • Tx receptor on platelet membrane binds
    thromboxin
  • P2Y12 receptor on platelet membrane
    binds ADP
  • GPIIbIIIa crosslinks with fibrinogen to
    crosslink with further platelets (fibrinogen
    between two platelets)
  • activated platelets generate thromboxane
    A2 from arachidonic acid using enzyme
    cyclooxygenase (platelet agonists)
  • binds to Tx receptor on other platelets
    promoting more aggregation, adhesion
    and activation
  • thrombin and ADP are also platelet
    agonists
  • cyclooxygenase results in the release of
    prostacyclin from the endothelium, which
    inhibits platelet aggregation (acts as a
    negative feedback loop) and causes
    vasodilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Bernard souilier disease

A
  • deficiency of GP Ib-IX-V complex
  • hard to form platelet plug
    platelets not tethered to Von Willebrand’s
    Factor
  • platelet disorder leads to increased bleeding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Glanzmann’s thrombasthenia

A
  • bleeding disorder
  • deficiency of GPIIbIIIa
  • can’t recruit and aggregate platelets
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Core Drug: Aspirin:
- chemical name
- common uses (2)

A
  • acetylsalicylic acid
  • has anti-inflammatory effects so often
    used for fever/pain
  • disrupts platelet function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Core Drug: Aspirin: side effects:

A
  • peptic ulceration
  • rash
  • hearing loss/tinnitus (high doses)
  • Reye’s Syndrome:
    - brain and liver damage in children
    given aspirin for viral illnesses
  • *** DO NOT GIVE CHILDREN
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Core drug: Aspirin: Mechanism of Action:

A
  • blocks production of prostaglandins and
    thromboxanes
  • aspirin is an IRREVERSIBLE inhibitor of
    cyclooxygenase 1 (COX 1 )
  • cyclooxygenase 1 converts arachidonic acid
    into thromboxane A2 into useable form
  • hence no further aggregation, adhesion
    and activation of platelets as without
    thromboxane less cross-linking between
    platelets
  • WILL ALSO INHIBIT RELEASE OF
    PROSTACYCLIN AT HIGH DOSES (COUNTER-
    INTUITIVE) 5grams a day is high
  • Gastric lining resistance to acid is
    prostaglandin dependent and hence side
    effects of gastric and peptic ulceration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cyclooxygenase 1 causes release of —– from injured endothelium resulting in —————- and ———-

A
  • prostacyclin
  • inhibits platelet aggregation
  • causes vasodilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Thromboxane A2 vs Prostacyclin

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

At low doses of aspirin,

A
  • selectively inhibits platelets
  • platelets can not synthesise new COX
  • endothelial can synthesise new COX
  • hence thromboxane A2 not released so
    less platelet aggregation and
    vasoconstriction
  • but prostacyclin released so inhibition of
    platelet aggregation and vasodilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Aspirin low doses

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Core Drug: Aspirin: Clinical Use: Arterial Disease:

A
  • in all patients with established vascular
    disease:
    - IHD (MI, angina)
    - Cerebrovascular Disease
    - Peripheral Vascular Disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Advantages of core drug aspirin use for arterial disease:

A
  • improves prognosis, less mortality, less
    adverse events (MI, stroke)
  • mainstay drug - cheap ++++
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Low dose of aspirin is

A

75-325 mg/day
300mg during MI
daily normal dose is 75mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Core Drug: Clopidogrel: Mechanism of action:

A
  • binds to P2Y12 receptor on platelet
  • inhibitor of P2Y12 receptor
  • combats acute coronary stent thrombosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clopidogrel vs aspirin

A
  • more effective than aspirin
  • similar safety profile
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clopidogrel vs aspirin

A
  • more effective than aspirin
  • similar safety profile
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Core Drug: Clopidogrel: Clinical Use:

A
  • part of “dual anti-platelet therapy” DAPT
  • post MI and elective coronary stenting
  • recurrent stroke despite aspirin
  • first line for peripheral arterial disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Core Drug: Clopidogrel: side effects:

A
  • bleeding; affects timing of major surgery
    (have to stop few days before)
  • rash
  • increased bleeding DAPT because two anti-
    platelets
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Core Drug: Clopidogrel: Resistance:

A
  • 30% do not get full effect
20
Q

Tirofiban: mechanism of action, side effects:

A
  • potent inhibitor of GPIIbIIIa, which
    crosslinks platelets via fibrinogen
  • “final common pathway” of platelet
    aggregation
  • very powerful anti-thrombotic drug
  • carries very high bleeding risk
  • only given during high risk coronary stent
    procedures: Primary PCI for STEMI, high
    risk coronary anatomy
21
Q

Summary of anti-platelet drugs:

A
22
Q

Core Drug: Warfarin: Mechanism of action and class:

A
  • Anti-coagulant
  • Vitamin K antagonist
  • inhibits gamma carboxylation of
    the vitamin K dependent coag
    factors 2,7,9,10 and production of
    proteins C and S
  • 2 = prothrombin (common)
  • 7 = extrinsic
  • 9 = intrinsic
  • 10 = common

1972 was the diSCo era

23
Q

Core Drug: Warfarin: Pharmacokinetics:

A
  • 3-4 day lag of effect
  • narrow therapeutic window:
    - monitor INR
    - aim for INR 2-3
24
Q

Core Drug: Warfarin: interactions:

A
  • alcohol
  • green veg
  • many drugs
  • metabolised by liver P450 enzyme
    group
25
Q

Core Drug: Warfarin: Clinical Uses:

A

First line:

  • mechanical heart valves
  • mitral stenosis with atrial fib

BEing superseded by DOACs:

  • stroke prophylaxis in AF
  • DVT
  • PE
26
Q

Warfarin: Side Effects:

A
  • bleeding: slow reversal with vitamin K, rapid reversal with blood factors
  • birth defects (teratogenic) = crosses
    placenta
  • Warfarin-induced skin necrosis:
    - protein C, S
    - transient hypercoagulable state
    on warfarin induction
    - so overlap with heparin
27
Q

Core Drug: Heparin: molecular mechanism and class:

A
  • anti-coagulant
  • unfractionated heparin
  • binds to and activates anti-
    thrombin
  • antithrombin inhibits coagulation l
    factors:
  • 2 = thrombin = common
  • 7 = extrinsic
  • 9 = intrinsic
  • 10 = intrinsic
  • 11 = intrinsic
  • 12 = intrinsic
  • 2+7= 9….10,11,12
  • mainly inhibits intrinsic pathway
    hence can measure using APTT
28
Q

Core Drug: Tinzaparin: Molecular mechanism and class:

A
  • anti-coagulant
  • low molecular weight heparin
  • binds to and activates anti-
    thrombin
  • antithrombin inhibits coagulation
    factors:
  • 2 = thrombin = common
  • 7 = extrinsic
  • 9 = intrinsic
  • 10 = intrinsic
  • 11 = intrinsic
  • 12 = intrinsic
  • 2+7= 9….10,11,12
  • mainly inhibits intrinsic pathway
    hence can measure using APTT
29
Q

Core Drug: Enoxaparin: molecular mechanism and class:

A
  • anti-coagulant
  • low molecular weight heparin
  • binds to and activates anti-
    thrombin
  • antithrombin inhibits coagulation
    factors:
  • 2 = thrombin = common
  • 7 = extrinsic
  • 9 = intrinsic
  • 10 = intrinsic
  • 11 = intrinsic
  • 12 = intrinsic
  • 2+7= 9….10,11,12
  • mainly inhibits intrinsic pathway
    hence can measure using APTT
30
Q

A patient with a metallic valve is anticoagulated, would you give:

A = heparin
B = warfarin with INR target 2 to 3
C = DOAC
D = warfarin with INR target for 3 to 4

A

b = warfarin

31
Q

Core Drug: Heparin: Pharmacology:

  • how quickly effects seen
  • route of administration
  • measurement
  • efficacy
A
  • rapid onset of action
  • IV or IS
  • units
  • Variable efficacy: monitor effect,
    APTT, aim for 1.5-2.5 x control
32
Q

Core Drug: Heparin: Side Effects:

A
  • bleeding
  • antidote: protamine-potent
    vasodilator
  • HIT
33
Q

Core Drug: Tinzaparin: Side Effects:

A
  • bleeding
  • antidote: protamine-potent
    vasodilator
  • HIT
34
Q

Core Drug: Enoxaparin: Side Effects:

A
  • bleeding
  • antidote: protamine-potent
    vasodilator
  • HIT
35
Q

Core Drug: When is unfractionated heparin used? Why?

A
  • chronic kidney disease
  • dialysis, bypass machines etc
  • VERY LARGE PULMONARY EMBOLI

bit safer

36
Q

Core Drug: Enoxaparin/Tinzaparin: Pharmacology:
- route of administration
- efficacy
- clearance?

A
  • subcutaneously
  • very reliable absorption, no
    monitoring required
  • RENAL CLEARANCE
37
Q

Core Drug: Enoxaparin/ Tinzaparin: Clinical Uses:

A

Acute:
- MI
- AF
- PE, iliofemoral DVT
- VTE prophylaxis

38
Q

Side effect of any heparin is HIT. What is HIT?

A
  • heparin induced thrombocytopenia
  • very dangerous
  • caused by antibodies
  • bind to complexes of heparin and
    platelet factor 4:
    - activates platelets causing
    prothrombotic effect
    - falling platelet count
    - extension of a previously
    diagnosed blood clot, or a new
    blood clot elsewhere (skin
    necrosis)
39
Q

What does DOAC stand for?

A

Direct Oral AntiCoagulants

40
Q

Core Drug: Dabigatran: Molecular mechanism and class:

A
  • anticoagulant
  • DOAC
  • direct inhibitor of thrombin
    (coagulation factor 2)
  • affects the conversion of fibrinogen
    into fibrin monomer and ultimately
    into fibrin clots
41
Q

Core Drug: Rivaroxaban: Molecular Mechanism and Class:

A
  • anticoagulant
  • DOAC
  • directly inhibitcoagulation factor Xa
    (10)
  • less thrombin generated from
    prothrombin
42
Q

Core Drug: Dabigatran: Clinical Uses:

A
  • DVT
  • pulmonary embolism
  • atrial fibrillation
  • post hip/knee prophylaxis
43
Q

Core drug: Rivaroxaban: Clinical Uses:

A
  • DVT
  • pulmonary embolism
  • atrial fibrillation
  • post hip/knee prophylaxis
44
Q

Benefits of DOACs than Warfarin

A
  • more reliable action:
    - higher dose = more effective,
    same bleeding
    - lower doses = as effective, less
    bleeding
    - no monitoring of effect
  • fewer interactions than warfarin
45
Q

Core Drug: Dabigatran: Are effects reversible?

A

Antidote: Idarucizumab

46
Q

Core Drug: Rivaroxaban: Are effects reversible?

A

Antidote: Andexanet